分化型甲状腺癌疾病相关死亡患者的初诊疾病严重程度:对2015年ATA指南的启示
研究纳入1374例分化型甲状腺癌患者,其中56例确认死于该病,53例数据充分可分析。中位诊断至死亡时间9年,89%初诊为ATA高危,无低危患者,88%为IV期。结论支持对低危组采用较少侵入性治疗策略。
要点
- 53例疾病相关死亡患者中,初诊时89%为ATA高危,6%为中危,无一例为低危。
- 88%的患者初诊时即为IV期,仅8%为I期,且I期患者均<45岁并伴侵袭性特征。
- 中位诊断至死亡时间为9年,死因46例与远处转移相关,7例与颈部侵袭性疾病相关。
核心结论
- 无疾病相关死亡患者初诊时具有低危特征,支持当前对低危组采用较少侵入性治疗策略的模式。
研究设计与样本
- 从Rabin甲状腺癌登记处和Davidoff头颈癌服务数据库纳入有记录的DTC疾病相关死亡患者,回顾病历分析初诊疾病特征、治疗、病程和死因。
- 共审查1374例患者病历,56例确认死于DTC,53例数据充分纳入分析。
主要发现
- 中位诊断至死亡时间为9年(范围1-36年)。
- 死因与远处转移相关46例,与颈部侵袭性疾病相关7例。
- 初诊中位年龄62岁(范围22-83岁),83%年龄大于45岁。
- 初诊ATA危险分层:高危89%(其中4例因甲状腺球蛋白水平高),中危6%(3例老年N1b疾病患者),1例误分类为良性,无低危患者。
- 初诊分期:IV期88%,III期2%,II期2%,I期8%;I期患者均<45岁且伴侵袭性特征(1例低分化,3例大体甲状腺外侵犯);1例II期患者<45岁且伴远处转移。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The current trend of less aggressive treatment of low-risk differentiated thyroid cancer (DTC) patients was recently challenged by a study reporting >10% disease-related mortality (DRM) in low-risk patients ablated with radioiodine activities below 54 mCi. However, this study and others were limited by incomplete data on disease severity at presentation. Whether patients presenting with low-risk disease are at risk for disease-related mortality is crucial for planning current treatment strategies. METHODS: Patients with documented DRM from DTC were included from the Rabin thyroid cancer registry and the Davidoff Head and Neck cancer service databases. Disease characteristics at presentation, treatments, disease course, and cause of death were analyzed. RESULTS: Of 1374 patients whose charts were reviewed, 56 were confirmed to have died of DTC, and 53 had sufficient data for analysis. Median time from diagnosis to death was 9 years (range 1-36). Cause of death was related to distant metastases in 46 patients and aggressive neck disease in 7 patients. The median age at diagnosis was 62 years (range 22-83, 83% older than 45), and were initially categorized as American Thyroid Association high risk in 89% of cases (in 4 cases due to high thyroglobulin levels), intermediate risk in 6% (3 older patients with N1b disease), misclassification as benign in one case, and none was low risk. Most patients had an advanced disease stage (stage IV, 88%; III, 2%; II, 2%; I, 8%). All patients with stage I disease were <45 years, with aggressive features (1 poorly differentiated, 3 gross extrathyroidal extension). One patient with stage II disease was <45 years and had distant metastases. Detection of distant metastases occurred within the first year in 25 patients and during subsequent follow-up in 25 patients. Overall, aside from one patient who was misdiagnosed as having a benign follicular adenoma at presentation, all patients had aggressive disease features at presentation. CONCLUSION: None of the patients with DRM had low-risk features at presentation, supporting the current paradigm of less aggressive approach in the low-risk group. Studies analyzing mortality from thyroid cancer should stratify patients into the various risk categories based on full baseline data, including postoperative thyroglobulin levels.
引用
- Robenshtok E, Nachalon Y, Benbassat C, et al. Disease Severity at Presentation in Patients with Disease-Related Mortality from Differentiated Thyroid Cancer: Implications for the 2015 ATA Guidelines. Thyroid. 2017. PMID: 28791923. doi:10.1089/thy.2017.0040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。